Upstream Bio (UPB) Capital Expenditures (2024 - 2025)
Upstream Bio (UPB) recorded quarterly Capital Expenditures of $110000.0 in Q4 2025, up 1275.0% quarter-over-quarter from $8000.0 in Q3 2025, and down 70.9% on a YoY basis from $378000.0 in Q4 2024.
Upstream Bio (UPB) Capital Expenditures (2024 - 2025) Analysis & Trends
Upstream Bio's Capital Expenditures history runs 2 years deep, the most recent figure standing at $110000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures fell 70.9% year-over-year to $110000.0; the TTM figure through Dec 2025 stood at $496000.0 (changed N/A YoY), while the FY2025 annual figure was $165000.0, down 67.71% from the prior year.
- Capital Expenditures was $110000.0 for Q4 2025 at Upstream Bio, up from $8000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $378000.0 in Q4 2024 to a low of $8000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110,000.00 |
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Dec 31, 2024 | 378,000.00 |
| Dec 31, 2024 | 378,000.00 |